Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer On Track To Settle Rapamune Investigation; Protonix Probe Still Unresolved

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.

You may also be interested in...



Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA

Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.

Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved

Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.

Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government

Pfizer reaches separate settlements with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel